公开(公告)号：US20190202911A1

公开(公告)日：2019-07-04

申请号：US16331171

申请日：2017-09-07

Applicant: Daiichi Sankyo Company, Limited

Inventor： Ryuta Mukasa ,  Kensuke Nakamura ,  Sumie Muramatsu ,  Naoyuki Makita

IPC: C07K16/28 ,  A61P37/06

CPC classification number: C07K16/2803 ,  A61K31/56 ,  A61K39/395 ,  A61K45/00 ,  A61K2039/505 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C12N5/10 ,  C12N15/09

Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.

公开(公告)号：US20240400681A1

公开(公告)日：2024-12-05

申请号：US18767925

申请日：2024-07-09

Applicant: Daiichi Sankyo Company, Limited

Inventor： Ryuta Mukasa ,  Kensuke Nakamura ,  Sumie Muramatsu ,  Naoyuki Makita

IPC: C07K16/28 ,  A61K31/56 ,  A61K35/12 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09

Abstract: Provided are methods for producing a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert human T cell suppression function.

公开(公告)号：US12071478B2

公开(公告)日：2024-08-27

申请号：US16331171

申请日：2017-09-07

Applicant: Daiichi Sankyo Company, Limited

Inventor： Ryuta Mukasa ,  Kensuke Nakamura ,  Sumie Muramatsu ,  Naoyuki Makita

IPC: A61P21/00 ,  A61K31/56 ,  A61K39/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  A61K35/12

CPC classification number: C07K16/2803 ,  A61K31/56 ,  A61K39/0008 ,  A61K39/395 ,  A61K45/00 ,  A61P1/04 ,  A61P3/10 ,  A61P5/16 ,  A61P7/04 ,  A61P7/06 ,  A61P17/00 ,  A61P17/06 ,  A61P19/02 ,  A61P21/00 ,  A61P21/04 ,  A61P25/00 ,  A61P27/02 ,  A61P29/00 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K16/28 ,  C07K16/46 ,  C12N5/10 ,  C12N15/09 ,  A61K2035/122 ,  A61K2039/505 ,  A61K2039/577 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided are methods for treatment or prevention of an autoimmune disease that comprise administering a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.

公开(公告)号：US10647769B1

公开(公告)日：2020-05-12

申请号：US16677506

申请日：2019-11-07

Applicant: Daiichi Sankyo Company, Limited

Inventor： Ryuta Mukasa ,  Kensuke Nakamura ,  Sumie Muramatsu ,  Naoyuki Makita

IPC: A61K39/395 ,  C07K16/28 ,  A61P1/04 ,  A61P31/00 ,  A61P7/06 ,  A61P43/00 ,  A61P17/06 ,  A61P17/00 ,  A61P37/02 ,  A61P35/00 ,  A61P27/02 ,  A61P19/02 ,  C07K16/46 ,  A61P5/16 ,  A61P37/08 ,  A61P29/00 ,  C12N15/09 ,  A61P21/04 ,  A61P37/06 ,  A61K31/56 ,  A61K45/00 ,  A61P21/00 ,  A61P7/04 ,  C12N5/10 ,  A61P3/10 ,  A61P25/00 ,  A61K39/00

Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.